T-Therapeutics raises $59M in series A for T-cell receptors

Newco T-Therapeutics Ltd. has raised £48 million (US$59 million) in a series A to advance development of T-cell receptors generated by its transgenic mouse platform for the treatment of solid tumors, autoimmune diseases and infections.

Related Keywords

,Newco Ltd ,Newcot Therapeutics ,T Therapeutics Ltd ,T Cell Receptors ,Gtcr ,Cancer Immunotherapy ,Kymab Ltd ,